On June 12, 2025, the Food and Drug Administration approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
Similar Posts
Fagron Compounding Services. Wichita, KS. 483 issued 08/08/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 08/08/2025
Short Title (70 char) Fagron Compounding Services. Wichita, KS. 483 issued 08/08/2025
FEI Number 3012104093
Firm Name Fagron Compounding Services
Record Type 483
State KSInotiv Inc. – 10/24/2025
Inotiv Inc. – 10/24/2025. Country: United States. Record Type: 483www.d-pharmacy.com – 711075 – 07/16/2025
Unapproved New Drugs/MisbrandedSymptomatic Nonerosive Gastroesophageal Reflux Disease: Developing Drugs for Treatment
Symptomatic Nonerosive Gastroesophageal Reflux Disease: Developing Drugs for TreatmentBAKKAVOR USA Issues Allergy Alert for 16-Ounce Meal Simple Red Lentil Dal Soup Due to Undeclared Milk
Charlotte, NC (December 9, 2025) – Bakkavor USA of Charlotte, North Carolina, is initiating a recall of 16-ounce Meal Simple brand Red Lentil Dal Soup, BEST BY 1/11/2026 as it contains undeclared milk. People who have an allergy or severe sensitivity to milk run the risk of serious or life-threateniPain and Arthritis Products Containing Hidden Ingredients
Learn about the warnings for pain and arthritis products that contain hidden drugs and other hidden ingredients.